Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism - Erem, C; Kocak, M; Nuhoglu, I; Yilmaz, M; Ucuncu, O (Eur J Endocrinol, 2009)